Peer-reviewedCC BY-NC-ND 4.0Scientific Reports
Safety and efficacy of lacnotuzumab, a colony-stimulating factor 1 antibody for the treatment of tenosynovial giant cell tumors: a randomized phase II trial
Related
- Efficacy and safety of adipose tissue-derived cell therapy in the treatment of chronic extremity ulcers: a systematic review and meta-analysis of randomized controlled trials
- Central nervous system efficacy of third generation vs. first generation EGFR-TKIs in the first line treatment for EGFR-mutated non-small cell lung cancer with central nervous system metastases: a systematic review and meta-analysis of phase 3 randomized controlled trials
- Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial
- Association of granulocyte colony-stimulating factor and immature neutrophils with treatment resistance in Kawasaki disease
- Cognitive remediation in schizophrenia: efficacy and role of neuroplasticity in “top-down” and “bottom-up” mechanisms—a randomized, double-blind, treatment-as-usual-controlled study protocol
BibTeX
@article{cheng2026safety,
title = {{Safety and efficacy of lacnotuzumab, a colony-stimulating factor 1 antibody for the treatment of tenosynovial giant cell tumors: a randomized phase II trial}},
author = {Edward Cheng and Ursula Schramm and Alireza Mirzaei and Franziska Saxer and Didier Laurent and Romana Lowcock and Thomas Peters and Marie-Anne Valentin and Marion Wiesmann and Pascale Pinot and Jens Praestgaard and Heng Zou and John A. Abraham and Joel A. Block and Marta Batus and Steven Gitelis and Robert M. Henshaw and Breelyn A. Wilky and Andreas H. Krieg and Anna A. Khachatrian and Jonathan C. Trent and Hiram F. Correa and Evan Beckmann and Ronenn Roubenoff and Matthias Schieker},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-74361-2},
url = {https://www.nature.com/articles/s41598-026-74361-2},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Safety and efficacy of lacnotuzumab, a colony-stimulating factor 1 antibody for the treatment of tenosynovial giant cell tumors: a randomized phase II trial
AU - Edward Cheng
AU - Ursula Schramm
AU - Alireza Mirzaei
AU - Franziska Saxer
AU - Didier Laurent
AU - Romana Lowcock
AU - Thomas Peters
AU - Marie-Anne Valentin
AU - Marion Wiesmann
AU - Pascale Pinot
AU - Jens Praestgaard
AU - Heng Zou
AU - John A. Abraham
AU - Joel A. Block
AU - Marta Batus
AU - Steven Gitelis
AU - Robert M. Henshaw
AU - Breelyn A. Wilky
AU - Andreas H. Krieg
AU - Anna A. Khachatrian
AU - Jonathan C. Trent
AU - Hiram F. Correa
AU - Evan Beckmann
AU - Ronenn Roubenoff
AU - Matthias Schieker
PY - 2026
DA - 2026/10/23
JO - Scientific Reports
DO - 10.1038/s41598-026-74361-2
UR - https://www.nature.com/articles/s41598-026-74361-2
SN - 2045-2322
ER -